Clinical trials: Head Neck Cancer Squamous Cell Recurrent
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This randomized phase II trial studies how well cisplatin with or without WEE1 inhibitor MK-1775 works in treating patients with head and neck cancer that has come back or has spread to other parts of the body.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT02196168
- Testing
- Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in Canada
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Head Neck, Squamous Cell Carcinoma of Head and Neck
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
To learn if magrolimab, along with a combination of commercially-available drugs (cetuximab, pembrolizumab, and docetaxel) can help to control HNSCC in combination with other drugs. The safety of magrolimab will also be studied.
- Trial name
- NCT06046482
- Testing
- Pembrolizumab, Magrolimab, cetuximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma
Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients
To establish whether LJM716 in combination with cetuximab is safe and has beneficial effects in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT02143622
- Testing
- LJM716, cetuximab
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00083057
- Testing
- gefitinib, paclitaxel, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
The standard of care for head and neck and lung cancer includes chemotherapy, radiation and surgery. For patients with cancer of head and neck or lung that recurs after surgery and/or radiation, or has spread to other parts of…
- Trial name
- NCT00901537
- Testing
- Azacitidine and Cisplatin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Loma Linda University
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Head and Neck Squamous Cell Carcinoma
Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China
This trial is main evaluate the efficacy and safety of pembrolizumab in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma with PD-L1 CPS≥20.
- Trial name
- NCT04740996
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shi Yuankai
Esophageal Cancer, Gastric Cancer
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005599
- Testing
- bryostatin 1, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Oral Complications of Radiation Therapy
CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy
RATIONALE: Lactobacillus bevis CD2 lozenge may help prevent symptoms of mucositis, or mouth sores, in patients receiving radiation therapy and chemotherapy.
- Conditions
- Head and Neck Cancer, Oral Complications of Radiation Therapy, Pain, Weight Changes
- Trial name
- NCT01545687
- Testing
- Lactobacillus brevis CD2 lozenge
- Sponsor
- Alliance for Clinical Trials in Oncology
Head and Neck Squamous Cell Carcinoma
A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers
This is a non-randomized, phase II, open label study of apatinib mesylate tablets plus tegafur gimeracil oteracil potassium capsules in recurrent/metastatic squamous cell carcinoma of head and neck.
- Trial name
- NCT03096184
- Testing
- Apatinib Mesylate Tablets, Tegafur Gimeracil Oteracil Potassium Capsules
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Head and Neck Cancer
Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Giving a nutritional supplement containing arginine, omega-3 fatty acids, and nucleotides to patients undergoing chemotherapy and radiation therapy may stimulate the immune system and help the body build a stronger…
- Trial name
- NCT00559156
- Testing
- arginine/omega-3 fatty acids/nucleotides oral supplement, cisplatin, adjuvant therapy
- Volunteers
- 46 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Esophageal Squamous Cell Carcinoma
KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
This is an open-label, phase II study of KN046 combined with chemotherapy and palliative radiotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma to evaluate the safety, efficacy and tolerance.
- Trial name
- NCT03927495
- Testing
- KN046, palliative radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Chest Hospital
Head and Neck Neoplasms, Squamous Cell Carcinoma
Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer
Metformin plus paclitaxel for recurrent or metastatic head and neck cancer: a randomized phase II trial
- Trial name
- METTAX (NCT01333852)
- Testing
- metformin up to 2500mg/d, paclitaxel 175mg/m² q21d
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- Lucas Vieira dos Santos
Esophageal Squamous Cell Carcinoma
Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer
This phase Ⅱ study was designed to evaluate the efficacy and safety of endostar combined with paclitaxel and nedaplatin as first-line therapy in treating patients with recurrent or metastatic esophageal squamous cell cancer.
- Trial name
- NCT02350517
- Testing
- Paclitaxel+Nedaplatin+Endostar
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Yuhong Li
Squamous Cell Carcinoma of Head and Neck
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
CMP-001-007 is a Phase 2 study of CMP-001 intratumoral (IT) and pembrolizumab intravenous (IV) administered to participants with head and neck squamous cell carcinoma (HNSCC) who have not been previously treated with a programmed…
- Trial name
- NCT04633278
- Testing
- CMP-001, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Head and Neck Cancer
Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Using a customized headrest to hold patients in one position may help doctors plan treatment for patients with head and neck cancer.
- Trial name
- NCT00973947
- Testing
- questionnaire administration, 3-dimensional conformal radiation therapy, radiation therapy treatment planning/simulation
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- Cancer Trials Ireland
Head and Neck Cancer
Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy following surgery in treating patients who have recurrent or second primary…
- Trial name
- NCT00004226
- Testing
- radiation therapy
- Where
- 3 sites in United States
- Sponsor
- University of Alabama at Birmingham
Head and Neck Squamous Cell Carcinoma
Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Because of the advantageous activity against VEGF-C and FGF pathways and favorable toxicity profile comparing with sunitinib, the investigators plan this phase II trial of pazopanib in cisplatin-refractory recurrent or metastatic…
- Trial name
- NCT01377298
- Testing
- Pazopanib
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- National Taiwan University Hospital
Solid Tumors
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
- Trial name
- NCT04704154
- Testing
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 175 people
- Sponsor
- Bayer